Corporate Communications:
Dr. Lise Hébert
(450) 680-4500
Toll free (877) 680-4500
If you need additional assistance or information regarding the company, please
send an Email to:
webinfo@neurochem.com.
December 22, 2004
- Neurochem Inc. announces the signing of exclusive collaboration and distribution agreement for
Fibrillex™ with Centocor, Inc.
Ecublens (Switzerland) December 22, 2004 - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary
of Neurochem Inc. (NASDAQ: NRMX; TSX: NRM), today...
(learn more by clicking here)
December 10, 2004
- Neurochem announces appointment of Mr. Mariano Rodriguez as Vice President, Finance and
Chief Financial Officer.
The Company announces the departure of Mr. Claude Michaud.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) today announced the appointment of Mr. Mariano Rodriguez, C.A., C.P.A., to the
position of Vice President, Finance, and Chief Financial Officer...
(learn more by clicking here)
December 7, 2004
- Neurochem announces completion of Phase II/III clinical trial for Fibrillex™.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today the completion of the treatment phase of the double-blind,
placebo-controlled, randomized and international Phase II/III clinical trial...
(learn more by clicking here)
November 8, 2004
- Neurochem to present at CIBC World Markets 15th Annual Healthcare Conference.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that on Tuesday, Nov. 9, 2004, Francesco Bellini, PhD,
Chairman and CEO, will present Neurochem's overall strategy and...
(learn more by clicking here)
November 4, 2004
- Neurochem reports results for third quarter of fiscal 2004.
Neurochem will host a conference call Thursday, Nov. 4, at 5:00 P.M. ET.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) today announced results for the third quarter of fiscal 2004, ended September 30.
The Company reported a net loss of $13,775,000 ($0.45 per...
(learn more by clicking here)
October 5, 2004
- Neurochem appoints Dr. Andreas Orfanos to position of Executive Vice President, Strategic Planning and
Scientific Affairs.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) today announced the appointment of Andreas Orfanos, M.B.B.Ch, MBA to the
position of Executive Vice President, Strategic Planning and...
(learn more by clicking here)
September 23, 2004
- Neurochem to present at 2004 UBS Global Life Sciences Conference and at CIBC World Markets Frontenac
Institutional Investor Conference.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that on September 29, 2004, Francesco Bellini, PhD, Chairman
and CEO, will present Neurochem's overall strategy and...
(learn more by clicking here)
August 20, 2004
P.P. Luxco Holdings II s.a.r.l., a wholly-owned subsidiary of Picchio Pharma Inc., announced today
that it has acquired an additional 350,000 common shares of Neurochem Inc. representing 1.16%...
(learn more by clicking here)
"Reuters Health, August 6, 2004"
"BioWorld Today, August 12, 2004"
"Nature, August 2004"
August 13, 2004
- Neurochem reports results for second quarter of fiscal 2004 and closing of $10.5 million bank
financing.
Neurochem will host a conference call Monday, Aug. 16, at 8:30 A.M. EDT.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) today announced results for the second quarter of fiscal
2004, ended June 30. The Company reported a net loss of $14,072,000 ($0.47 per share)...
(learn more by clicking here)
August 9, 2004
- Neurochem Inc. - No material information that would explain recent trading of common shares.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) today confirmed that it is not aware of any material information that would explain the recent trading
over the last several sessions of its common...
(learn more by clicking here)
July 21, 2004
- Neurochem's lead product candidate, Alzhemed™, one of three highlighted at Alzheimer's
Association News Conference.
During its international conference held in Philadelphia, the Alzheimer's Association of the
United States highlighted Alzhemed™ as a promising treatment for Alzheimer's Disease...
(learn more by clicking here)
July 18, 2004
- Neurochem's on-going open-label Phase II extension study for Alzhemed™ shows continued
positive interim results in Alzheimer's Disease patients after 20 months.
Conference Call and live webcast on July 19, at 10:00 A.M.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that interim results of an on-going
open-label Phase II extension study of the effects of Alzhemed™ on cognitive function and...
(learn more by clicking here)
July 16, 2004
- Neurochem to hold conference call and webcast on interim Alzhemed™ results unveiled at
9th International Conference on Alzheimer's Disease and Related Disorders.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) will hold a conference call on Monday, July 19, 2004, at
10:00 A.M., EDT, to discuss the latest interim clinical results of the Phase II...
(learn more by clicking here)
July 15, 2004
- Neurochem to present findings at the 9th International Conference on Alzheimer's Disease
and Related Disorders.
Presentation of interim clinical data on Alzhemed™ for the treatment of
Alzheimer's Disease.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that it will make two oral presentations
and will have two posters at the 9th International Conference on Alzheimer's Disease and...
(learn more by clicking here)
July 7, 2004
- Neurochem's Fibrillex™ selected for new FDA Pilot 2 program.
Fibrillex™ Already Granted Fast-Track Product Designation.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that Fibrillex™, the Company's
investigational product candidate for the treatment of Amyloid A (AA) Amyloidosis, has been...
(learn more by clicking here)
June 22, 2004
- Neurochem to present at the second annual "TSX Canada Day in New York City" event.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that on June 23, 2004, Dr. Francesco Bellini,
Chairman and CEO of Neurochem, will present an overview of the Company and its...
(learn more by clicking here)
June 21, 2004
- Neurochem announces the launch of North American Phase III clinical trial on
Alzhemed™ for the treatment of Alzheimer's Disease.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that it has launched its North American Phase
III clinical trial on Alzhemed™, following an investigators' meeting attended by...
(learn more by clicking here)
June 16, 2004
- Neurochem to present at Needham & Company Third Annual Biotechnology Conference.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that on June 17, 2004, Dr. Lise
Hébert, Vice President, Corporate Communications, will present Neurochem's overall strategy and...
(learn more by clicking here)
June 8, 2004
- Dr. Francesco Bellini receives the Ordre national du Québec.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) is pleased to announce that the Premier of Quebec, Mr. Jean
Charest, has appointed Dr. Francesco Bellini, Neurochem's Chairman and...
(learn more by clicking here)
May 20, 2004
- Neurochem to present at Banc of America Securities' Health Care Conference and at
UBS 2004 Global Specialty Pharmaceuticals Conference.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that on Friday, May 21, 2004, Dr.
Francesco Bellini, Chairman and CEO, will present Neurochem's overall strategy and progress to...
(learn more by clicking here)
May 19, 2004
- Annual General Meeting of Shareholders.
Neurochem emphasizes progress on clinical pipeline.
At its annual general meeting of shareholders, Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) emphasized
solid progress in the clinical development of its three key programs. The Company...
(learn more by clicking here)
May 18, 2004
- Neurochem's Annual General Shareholders' Meeting and media briefing session.
Dr. Francesco Bellini, Chairman and Chief Executive Officer of Neurochem Inc., invites the news
media to the Annual General Shareholders' Meeting that will be held on Wednesday, May 19...
(learn more by clicking here)
May 11, 2004
- Following Change in Year-end.
Neurochem reports results for first quarter of fiscal year 2004.
Neurochem will host a conference call today at 4:30 P.M. EDT.
Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - announced today results for the first quarter, ended
March 31, 2004, of its current fiscal year. For the quarter, the Company reported a net loss of...
(learn more by clicking here)
May 11, 2004
- Neurochem moves headquarters to former Shire Biochem facilities.
Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - is pleased to announce that it has moved all of its
employees to its new headquarters located in the state-of-the-art former...
(learn more by clicking here)
May 10, 2004
- Neurochem to report on first quarter of new fiscal year.
Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - today announced that on Tuesday, May 11, 2004, it will
release its first quarter 2004 results for the period ended March 31, 2004...
(learn more by clicking here)
April 27, 2004
- Neurochem to present at CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals
Conference.
Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - announced today that on Wednesday April 28, 2004, Dr.
Francesco Bellini, Chairman and CEO, will present Neurochem's overall strategy...
(learn more by clicking here)
April 27, 2004
- Neurochem announces promising Phase II results for Cerebril™ at the American Academy of
Neurology's 56th Annual Meeting.
Data Supports Further Clinical Development.
Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - will announce today, at the American Academy of Neurology's
56th Annual Meeting, promising results from its Phase II clinical trial for...
(learn more by clicking here)
April 26, 2004
- Neurochem receives fourth consecutive positive recommendation from Data Safety Monitoring Board to
continue Phase II/III Clinical Trial for Fibrillex™.
Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - announced today that its independent Data Safety
Monitoring Board (DSMB) has issued a fourth unanimous recommendation to continue the...
(learn more by clicking here)
April 14, 2004
- Neurochem announces additional positive results in on-going Phase II extension study for Alzhemed™.
Neurochem reports interim positive results in Alzheimer's patients after 16 months of treatment with
Alzhemed™ at 8th International Montreal/Springfield Symposium on Advances in Alzheimer Therapy.
Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - reported today additional positive interim data on
cognitive function in 18 patients with mild-to-moderate Alzheimer's Disease (AD). The results...
(learn more by clicking here)
April 13, 2004
- Neurochem invited to present findings on Alzheimer drug to Springfield Conference.
Symposium highlights Neurochem's Alzhemed™ as one of the most promising product candidates
for the treatment of Alzheimer's Disease
Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - announced today that it has been chosen as one of the
five group of researchers and companies that will be highlighted at the 8th International...
(learn more by clicking here)
April 8, 2004
- Neurochem consolidates operations as it reaches new level of growth.
Acquires State-of-the-Art Facilities for its New Headquarters.
Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - is pleased to announce today that the Company has signed
a conditional agreement to purchase the Shire BioChem facilities located in...
(learn more by clicking here)
March 30, 2004
- Neurochem to present at 11th Anniversary of Future Leaders in the Biotech Industry.
Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - announced today that it will present at the 11th
Anniversary of Future Leaders in the Biotech Industry organized by Thomson Financial and...
(learn more by clicking here)
February 23, 2004
- Neurochem reports results for its quarter and transitional financial year ended December 31, 2003.
Neurochem will host a conference call today at 4:30 P.M. EST.
Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - today announced results for its quarter and six-month
transitional financial year ended December 31, 2003. As previously announced...
(learn more by clicking here)
February 11, 2004
- Neurochem granted Fast Track Designation from U.S. FDA
for Fibrillex™.
The Company plans to file its U.S. NDA in 2005.
Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - today announced that the U.S. Food and Drug Administration
(FDA) has designated the Company's most advanced investigational drug candidate...
(learn more by clicking here)
January 22, 2004
- Additional Results In On-going Phase II Extension Study.
Neurochem reports interim positive results in Alzheimer's patients after 12 months
of treatment with Alzhemed™.
Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - reported today additional positive interim data on
cognitive function in the 30 patients with mild1-to-moderate2 Alzheimer's Disease
(AD)...
(learn more by clicking here)
January 20, 2004
To Support Its Synthetic Vaccine Program for
Alzheimer's Disease.
- Neurochem forms strategic alliance with the National Research Council of Canada and
announces licensing agreement with Praecis Pharmaceuticals Incorporated.
Neurochem Takes Major Step Forward in its Efforts to Prevent and Treat Alzheimer's Disease.
Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - announced today that the Company is advancing its efforts
to prevent and treat Alzheimer's Disease (AD) by forging a strategic alliance with the...
(learn more by clicking here)
January 16, 2004
- Appointments of Vice Presidents of Business Development and Human Resources.
Neurochem expands Management Team.
Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - announced today the appointment of two new vice presidents
to further support its professional management team as the Company approaches...
(learn more by clicking here)
January 14, 2004
- Neurochem's Data Safety Monitoring Board issues third recommendation to continue pivotal
phase 2/3 Clinical Trial for Fibrillex™.
Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - announced today that, following the third meeting of its
independent Data Safety Monitoring Board (DSMB), the Company has received its third...
(learn more by clicking here)
|
2008
Archives 2003
